Latest News

In an interview with Pharmacy Times, Erin J. Walsh, PharmD, RPh, MS, MCST, discusses how VER-01 could reshape the role of cannabis-derived medicines in chronic pain care, the evolving role of pharmacists, and why pharmaceutical cannabinoids and whole-plant cannabis should be viewed as complementary therapeutic options rather than competitors.

CGRP drugs and new PACAP targets are reshaping acute and preventive therapy.

A new toxicological risk assessment builds on 2024 findings that raised consumer concern, offering pharmacists reassuring data to share with patients.

Influenza vaccination preparation should be on the docket for any pharmacy, and it isn’t too early to start now.

Obesity must be treated as the lifelong, chronic condition it is, and pharmacists are essential to making that vision a reality.

Framing medications as common and normal improved patients' willingness to start therapy, whereas numerical adverse effect data had no significant impact.

A large US registry analysis found that men were more likely than women to be diagnosed with regional or distant disease across 20 nonreproductive cancer types.

A machine learning–triggered nephrology consultation did not reduce peak creatinine changes in hospitalized patients at high risk for stage 2 AKI.

The new drug application's submission is supported by data from the phase 3 clinical studies SynAIRgy and LunAIRo.

Understanding OTC oral and topical treatment options, plus lifestyle steps, helps pharmacists guide safer relief.

New data show mRNA-1010 diversifies B-cell responses well beyond what conventional hemagglutination-inhibition testing can capture.

In an interview with Pharmacy Times, Cherise Steib, PharmD, HDDP, discussed patient selection, caregiver requirements, cytokine release syndrome (CRS), immune effector cell–associated neurotoxicity syndrome (ICANS), and the American Oncology Network’s approach to building an outpatient bispecific therapy program.

Some commonly used treatments for chronic low back pain may offer limited benefit while increasing risks, underscoring the need for pharmacists to support evidence-based, patient-centered care.

Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPS (AQ-Cardiology), CACP, led a Pharmacy Times Clinical Forum on optimizing the management of patients with heart failure across practice settings.

Baseline proton pump inhibitor (PPI) use, and to a lesser extent, antibiotic use, was associated with reduced benefit from consolidation durvalumab after chemoradiotherapy in patients with unresectable stage 3 NSCLC.

Nephrology experts Ashish Verma, MBBS, and Sophie Claudel, MD, discuss why estimated glomerular filtration rate alone misses chronic kidney disease and how pharmacists can help drive earlier detection.

New PET imaging data show reduced dopamine nerve terminal density in patients with long COVID, correlating with fatigue, motor slowing, and memory problems.

Two clinicians—a psychiatric prescriber and a hospital clinical pharmacist—weigh in on when to add a glucagon-like peptide-1 receptor agonist for patients with serious mental illness, how to monitor for trouble, and how to set expectations at the counter.

AI functions as a supportive layer that improves efficiency while preserving the pharmacist’s central role in therapeutic decision-making.

Pharmacists proactively identify red flags for early detection, navigate complex insurance and access barriers for high-cost disease-modifying therapies, and serve as educators across settings.

Patients with cancer on semaglutide or tirzepatide face hidden drug-drug interactions such as slowed absorption and nausea, requiring antiemetics and pharmacist coordination.